# Tirzepatide Peptide

> Tirzepatide is a dual GIP and GLP-1 receptor agonist that improves glucose control, reduces appetite, and supports weight-management pathways.

Canonical: https://pepflow.app/peptides/tirzepatide/

The Dual Incretin

A once-weekly GIP and GLP-1 receptor agonist with strong human evidence for obesity and type 2 diabetes, plus obstructive-sleep-apnea data in adults with obesity.

Weight loss  Sleep

Tier S

Evidence Strong

Safety Well-Studied

FDA status Approved

Last reviewed October 25, 2026 49 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Tirzepatide?

Tirzepatide is a synthetic incretin drug that activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor. That dual signaling separates it from single-receptor GLP-1 agonists such as semaglutide.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

In obesity trials, tirzepatide produces large, dose-dependent weight reductions and strong maintenance data when treatment is continued.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/39536238/>)

For type 2 diabetes, tirzepatide improves glycemic outcomes and was directly compared with injectable semaglutide 1 mg in SURPASS-2. The comparison does not automatically cover all semaglutide obesity doses or tablet products.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

## What Tirzepatide is investigated for

Tirzepatide evidence is grouped by practical use case and injectable and sublingual route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Body-weight reduction Injectable 96% Strong

Tirzepatide is strongly supported for weight management when used as a labeled injectable product in the right population.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>)

#### Human evidence

SURMOUNT-1 and SURMOUNT-2 show substantial body-weight reductions in adults with obesity or overweight, including people with type 2 diabetes.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/37385275/>)

#### Animal / mechanistic evidence

Dual incretin signaling provides a plausible satiety and metabolic mechanism, but the confidence comes from phase 3 human data.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)

### ### Weight-loss maintenance Injectable 92% Strong

The maintenance evidence supports chronic-disease framing rather than short-cycle peptide use.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>)

#### Human evidence

SURMOUNT-4 showed that continuing tirzepatide maintained and extended weight reduction better than switching to placebo.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>)

#### Animal / mechanistic evidence

Maintenance likely depends on continued incretin-receptor pharmacology and appetite regulation rather than a permanent reset after stopping.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>)

### ### Type 2 diabetes glycemic control Injectable 92% Strong

The diabetes use case is strong but should be coordinated with other glucose-lowering drugs to manage hypoglycemia risk.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

#### Human evidence

Mounjaro labeling and SURPASS-2 support tirzepatide for glycemic control in type 2 diabetes.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>)

#### Animal / mechanistic evidence

GIP and GLP-1 receptor agonism increases glucose-dependent insulin signaling and helps regulate glucagon and appetite.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

### ### Obesity-related obstructive sleep apnea Injectable 85% Strong

This is a specific obesity-related sleep-apnea use case, not a general sleep-quality peptide claim.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/38912654/>)

#### Human evidence

SURMOUNT-OSA reported improvements in adults with obesity and obstructive sleep apnea, and Zepbound labeling includes this indication.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/38912654/>) [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)

#### Animal / mechanistic evidence

The most plausible pathway is weight reduction and related upper-airway/metabolic changes, not a direct sedative or sleep-hormone mechanism.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/38912654/>)

### ### Cardiovascular risk and heart failure Injectable 78% Moderate

Tirzepatide has meaningful cardiometabolic benefit evidence in selected populations, but not a blanket cardiovascular-risk claim for every user.[\[46\]](<https://pubmed.ncbi.nlm.nih.gov/41406444/>) [\[24\]](<https://pubmed.ncbi.nlm.nih.gov/39555826/>)

#### Human evidence

SURPASS-CVOT reported cardiovascular events versus dulaglutide in type 2 diabetes with atherosclerotic cardiovascular disease, and a separate trial studied heart failure with preserved ejection fraction and obesity.[\[46\]](<https://pubmed.ncbi.nlm.nih.gov/41406444/>) [\[24\]](<https://pubmed.ncbi.nlm.nih.gov/39555826/>)

#### Animal / mechanistic evidence

Weight, glycemic, blood-pressure, lipid, and inflammatory changes are plausible contributors, but interpretation should stay tied to the human trial populations.[\[44\]](<https://pubmed.ncbi.nlm.nih.gov/35210595/>)

### ### MASH resolution and liver fat Injectable 68% Moderate

MASH is a legitimate tirzepatide investigation area, but it should stay separate from general weight-loss positioning and should not be generalized into nonspecific liver detox claims.[\[47\]](<https://pubmed.ncbi.nlm.nih.gov/38856224/>) [\[22\]](<https://pubmed.ncbi.nlm.nih.gov/39903735/>)

#### Human evidence

The SYNERGY-NASH phase 2 trial reported MASH resolution without worsening fibrosis more often with tirzepatide than placebo over 52 weeks.[\[47\]](<https://pubmed.ncbi.nlm.nih.gov/38856224/>)

#### Animal / mechanistic evidence

The likely contributors include weight reduction, insulin-sensitivity changes, and broader metabolic effects rather than a liver-specific peptide replacement mechanism.[\[22\]](<https://pubmed.ncbi.nlm.nih.gov/39903735/>)

## Evidence snapshot

### Overall confidence

Strong

93%

Tirzepatide has strong human evidence across obesity, type 2 diabetes, weight-loss maintenance, and obesity-related obstructive sleep apnea in studied populations.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/38912654/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

96%

### Human evidence

Strong

SURMOUNT and SURPASS trials, FDA labeling, maintenance data, and head-to-head obesity evidence provide a large human dataset for route-specific injectable use.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40353578/>)

80%

### Animal / preclinical

Strong

Nonclinical and pharmacology support helps explain dual GIP and GLP-1 receptor activity, while human phase 3 outcomes carry the clinical confidence.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

90%

### Mechanism support

Strong

Dual incretin signaling gives a clear rationale for appetite, body-weight, glycemic, and cardiometabolic effects, with safety boundaries defined by the labeled injectable products.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

## Forms & administration

Tirzepatide is supplied as product-specific injections, including Mounjaro and Zepbound. Compounded sublingual products are also marketed, but their absorption and clinical effects remain unestablished. Their amounts and preparation cannot be equated with the labeled injectable medicines.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>) [\[3\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) [\[45\]](<https://pubmed.ncbi.nlm.nih.gov/41689811/>) [\[49\]](<https://www.fda.gov/media/185577/download>)

Injectable Sublingual

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Tirzepatide starts at 2.5 mg weekly for 4 weeks, then increases to 5 mg. Maintenance doses are 5 mg, 10 mg, or 15 mg weekly.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

### Frequency

Taken once weekly. Dose increases use 2.5 mg steps after at least 4 weeks.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

### Timing Considerations

Use the same day each week, at any time and with or without food. A missed dose can be taken within 4 days.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

### Cycle Length

Treatment is ongoing, with at least 4 weeks at each dose.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/39536238/>)

[Full Tirzepatide dosage guide](<https://pepflow.app/peptides/tirzepatide/dosage/>)

## What to expect

### First months

Appetite, cravings, and portion size often shift before the scale trend fully settles.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>)

### 6-18 months

Weight loss can keep accumulating across longer treatment, with waist change and appetite control often becoming more obvious over time.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>)

### Long term

Rapid new loss often gives way to maintenance, while cardiometabolic risk markers, diabetes-risk patterns, and sleep-apnea symptoms may reflect the sustained lower weight.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/39536238/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/38912654/>)

### After stopping

Appetite can return and weight regain is common after tirzepatide is stopped; cardiometabolic and sleep-apnea improvements may weaken if weight returns.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>) [\[19\]](<https://pubmed.ncbi.nlm.nih.gov/40186344/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/38912654/>)

## Safety profile

Tirzepatide has a prescription-drug safety profile with boxed thyroid C-cell tumor warning, common GI effects, pancreatitis and gallbladder warnings, kidney injury risk from dehydration, hypoglycemia risk with insulin or secretagogues, and oral-contraceptive interaction guidance.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

### Common side effects

- Nausea [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)
- Vomiting [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)
- Diarrhea [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)
- Constipation [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)

### Cautions

- Thyroid C-cell tumor warning[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)
- Oral contraceptive interaction guidance[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)
- Pancreatitis, gallbladder, or kidney risk[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)
- Insulin or sulfonylureas[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)
- Unapproved GLP-1/GIP products[\[3\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

## Who Tirzepatide is not for

Route-specific avoid and medical-review notes:

- **MTC or MEN2 history**

  Tirzepatide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Documented interactions

- **Insulin or sulfonylureas**

  Hypoglycemia risk may increase when tirzepatide is combined with insulin or insulin secretagogues.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)
- **Oral contraceptives**

  Tirzepatide can reduce oral hormonal contraceptive efficacy after initiation and dose escalation because delayed gastric emptying changes absorption; the label advises non-oral or backup contraception during those windows.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)
- **Oral drugs that need stable levels**

  Tirzepatide delays gastric emptying and may change absorption of oral medicines; labels flag extra monitoring for drugs that depend on threshold concentrations or have a narrow therapeutic index.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

## Pairing notes

### Works well with

**Nutrition and activity intervention** Injectable

Nutrition and activity help turn tirzepatide's appetite and weight effects into a repeatable plan: reduced-calorie eating, movement, and behavior routines remain the structure around the injection.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>)

### Not recommended with

**Semaglutide: overlapping GLP-1 effects** Injectable

Tirzepatide and semaglutide both activate GLP-1 pathways. Using them during overlapping courses duplicates effects on appetite, gastric emptying, and glucose control and requires clinician direction.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)

**Retatrutide: overlapping GIP and GLP-1 effects** Injectable

Tirzepatide and retatrutide both activate GIP and GLP-1 pathways. Overlapping them duplicates incretin effects and adds retatrutide's glucagon activity without an established combination regimen.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)

**Cagrilintide: added amylin appetite effects** Injectable

Cagrilintide adds amylin-mediated satiety to tirzepatide's GIP and GLP-1 effects. This combination falls outside studied CagriSema and has no established combined dosing or safety framework.[\[48\]](<https://pubmed.ncbi.nlm.nih.gov/40544433/>) [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)

## Regulatory status

### United States

United States: FDA-approved tirzepatide injection products exist under specific labels. Unapproved or compounded GLP-1/GIP products are a separate safety and regulatory concern.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>) [\[3\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Approved · Tirzepatide injection appears in FDA-approved labeling for Zepbound and Mounjaro; indication depends on the specific product label.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>) | Not Listed · FDA warns that unapproved GLP-1 products used for weight loss can create dosing, ingredient, quality, and adverse-event risks. This is separate from FDA-approved tirzepatide products.[\[3\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) |

### Injectable

FDA drug approval

Approved

Tirzepatide injection appears in FDA-approved labeling for Zepbound and Mounjaro; indication depends on the specific product label.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

503A compounding

Not Listed

FDA warns that unapproved GLP-1 products used for weight loss can create dosing, ingredient, quality, and adverse-event risks. This is separate from FDA-approved tirzepatide products.[\[3\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

### International

International status depends on country, product name, indication, and local prescribing rules.

### Sports & competition

Tirzepatide is not named as a prohibited substance in the reviewed 2026 WADA list, but athletes still need to follow medication, prescription, and event-specific rules.

## How it works

Tirzepatide is a dual GIP and GLP-1 receptor agonist with once-weekly exposure. That dual-incretin design connects appetite reduction with glucose-dependent insulin, glucagon, and insulin-sensitivity effects rather than simply adding another GLP-1 label.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>)

It also delays gastric emptying, strongest after early dosing, which helps explain fullness, nausea, and oral-medication timing concerns without making gastric slowing the whole weight-loss story.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)

The human confidence comes from SURMOUNT and SURPASS outcomes, not receptor theory alone; adding other incretin or satiety drugs can duplicate GI, dehydration, and glucose-management risks, so combinations belong in medication management.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>) [\[3\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

## Research gaps & open questions

What the current literature has not yet settled about Tirzepatide:

01

Long-term studies still need better answers on preserving muscle, maintaining nutrition, and keeping weight and metabolic benefits after stopping, especially in people unlike those enrolled in trials.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/39536238/>)

02

More direct comparisons across approved doses and real-world populations are needed to keep comparisons with semaglutide precise.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40353578/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>)

## Common questions

### Is tirzepatide a GLP-1 drug?

Partly. Tirzepatide activates GLP-1 receptors and GIP receptors, so it is better described as a dual incretin agonist.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)

### Is tirzepatide stronger than semaglutide?

Head-to-head and indirect comparisons favor tirzepatide for weight reduction in some settings, but exact interpretation depends on dose, route, product, and population.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40353578/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>)

### Why is sleep apnea included?

SURMOUNT-OSA studied tirzepatide in adults with obesity and obstructive sleep apnea, making this a specific obesity-related outcome rather than a general sleep claim.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/38912654/>)

## Myths & misconceptions

### Myth

Because tirzepatide is dual-action, it should be stacked with more GLP-1 peptides.

### Reality

Dual-action already means two receptor pathways are engaged. Adding overlapping incretin drugs is medication-level combination therapy, not a casual stack.[\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)

### Myth

All tirzepatide products are equivalent.

### Reality

FDA-approved products have reviewed labels, quality controls, and delivery systems. FDA has warned separately about unapproved GLP-1 products.[\[3\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)

## History & discovery

Tirzepatide marks the jump from single GLP-1 drugs to dual-incretin therapy. It entered as a once-weekly GIP/GLP-1 diabetes drug, then SURMOUNT trials made it a major obesity-treatment reference point and public clinical comparison anchor for readers.[\[2\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>) [\[1\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>)

SURPASS-2 defined the diabetes comparison with semaglutide 1 mg, and SURMOUNT-1 moved tirzepatide into obesity treatment with substantial weight reduction.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/34170647/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/35658024/>)

Maintenance, OSA, MASH, and SURMOUNT-5 comparator data broadened the story, while FDA materials kept approved tirzepatide separate from unapproved GLP-1/GIP products and informal supply claims.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/38078870/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/38912654/>) [\[47\]](<https://pubmed.ncbi.nlm.nih.gov/38856224/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/40353578/>) [\[3\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

## Published research 49 citations

- [\[1\] **ZEPBOUND (tirzepatide) injection prescribing information** U.S. Food and Drug Administration, 2026. regulatory.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf>)
- [\[2\] **MOUNJARO (tirzepatide) injection prescribing information** U.S. Food and Drug Administration, 2026. regulatory.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf>)
- [\[3\] **FDA's concerns with unapproved GLP-1 drugs used for weight loss** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)
- [\[4\] **FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list>)
- [\[5\] **Tirzepatide Once Weekly for the Treatment of Obesity** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/35658024/>)
- [\[6\] **Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34170647/>)
- [\[7\] **Tirzepatide for obesity treatment in people with type 2 diabetes** The Lancet. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37385275/>)
- [\[8\] **Tirzepatide for obstructive sleep apnea and obesity** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38912654/>)
- [\[9\] **Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity** JAMA. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38078870/>)
- [\[10\] **Tirzepatide for obesity treatment and diabetes prevention** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39536238/>)
- [\[11\] **Tirzepatide as compared with semaglutide for the treatment of obesity** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40353578/>)
- [\[12\] **SURMOUNT-1 tirzepatide weight-management trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT04184622>)
- [\[13\] **SURMOUNT-OSA tirzepatide obstructive sleep apnea trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05412004>)
- [\[14\] **Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials** Advances in therapy, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41820778/>)
- [\[15\] **A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial** Diabetes, obesity & metabolism, 2026. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41635114/>)
- [\[16\] **A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults** Nature medicine, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/41039116/>)
- [\[17\] **Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients** Journal of the American College of Cardiology, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40892610/>)
- [\[18\] **Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis** BMJ (Clinical research ed.), 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40813122/>)
- [\[19\] **Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis** Obesity reviews : an official journal of the International Association for the Study of Obesity, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40186344/>)
- [\[20\] **Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies** Endocrinology, diabetes & metabolism, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40184508/>)
- [\[21\] **Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight** Diabetes, obesity & metabolism, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39996356/>)
- [\[22\] **Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis** Hepatology (Baltimore, Md.), 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/39903735/>)
- [\[23\] **Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis** Metabolism: clinical and experimental, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/39719170/>)
- [\[24\] **Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity** The New England journal of medicine, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39555826/>)
- [\[25\] **Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials** Metabolism: clinical and experimental, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/39305981/>)
- [\[26\] **Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials** International journal of clinical pharmacy, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/39037553/>)
- [\[27\] **Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial** Endocrine, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38850440/>)
- [\[28\] **Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians** Annals of internal medicine, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38639549/>)
- [\[29\] **Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials** Diabetologia, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38613667/>)
- [\[30\] **Evidence that tirzepatide protects against diabetes-related cardiac damages** Cardiovascular diabetology, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38555463/>)
- [\[31\] **Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis** Obesity (Silver Spring, Md.), 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38413012/>)
- [\[32\] **Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials** Frontiers in public health, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38356942/>)
- [\[33\] **Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis** BMJ (Clinical research ed.), 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38286487/>)
- [\[34\] **Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis** Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38029929/>)
- [\[35\] **Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis** Frontiers in endocrinology, 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/37908750/>)
- [\[36\] **Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus** Diabetes, obesity & metabolism, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/37828829/>)
- [\[37\] **Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials** Diabetes, obesity & metabolism, 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/37700437/>)
- [\[38\] **Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials** International journal of obesity (2005), 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/37460681/>)
- [\[39\] **Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis** International journal of obesity (2005), 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/37253796/>)
- [\[40\] **Weight loss efficiency and safety of tirzepatide: A Systematic review** PloS one, 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/37141329/>)
- [\[41\] **Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials** BMJ (Clinical research ed.), 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/37024129/>)
- [\[42\] **Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials** Obesity reviews : an official journal of the International Association for the Study of Obesity, 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/36579723/>)
- [\[43\] **Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis** Diabetologia, 2022. review.](<https://pubmed.ncbi.nlm.nih.gov/35579691/>)
- [\[44\] **Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis** Nature medicine, 2022. review.](<https://pubmed.ncbi.nlm.nih.gov/35210595/>)
- [\[45\] **Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.** The Annals of pharmacotherapy, 2026 Sep. reference catalog.](<https://pubmed.ncbi.nlm.nih.gov/41689811/>)
- [\[46\] **Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes** New England Journal of Medicine, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41406444/>)
- [\[47\] **Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis** New England Journal of Medicine, 2024. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38856224/>)
- [\[48\] **Coadministered cagrilintide and semaglutide in adults with overweight or obesity** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40544433/>)
- [\[49\] **Resolution of Tirzepatide Injection Product Shortage and Supply Status** U.S. Food and Drug Administration, 2024-12-19. regulatory.](<https://www.fda.gov/media/185577/download>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Incretin/amylin analog

**Tier**

S

**Evidence**

93% Strong

**Safety**

Well-Studied

**FDA status**

Approved

**Injectable 503A**

Not Listed

**Citations**

[49 citations](<https://pepflow.app/peptides/tirzepatide/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Body-weight reduction
- Weight-loss maintenance
- Type 2 diabetes glycemic control
- Obesity-related obstructive sleep apnea
- Cardiovascular risk and heart failure
- MASH resolution and liver fat

### Common side effects

- Nausea
- Vomiting
- Diarrhea

### Also known as

- Tirzepatide
- Zepbound
- Mounjaro
- LY3298176

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Tirzepatide dosage guide](<https://pepflow.app/peptides/tirzepatide/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
